drugset / Trial / NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RandomizedParallel-groupSingle-blindTreatment
Summary
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Timeline
- Start
- 2025-08-11
- Primary completion
- 2027-11-04
- Completion
- 2027-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Megestrol Acetate | Other / unclassified | 80 mg | Oral |
| Subject | Opevesostat | Small molecule | 5 mg | Oral |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |
| Subject | medroxyprogesterone acetate | Other / unclassified | 80 mg | Oral |
| Background | Dexamethasone | Small molecule | 1 mg | Oral |
| Background | Fludrocortisone | Other / unclassified | 0.1 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | — | Intramuscular |